Powerful Cancer Diagnosis Software

Combining artificial intelligence and machine learning, we call it Smart Ultrasound.

What is Koios DS?

Koios Smart Ultrasound software provides early and accurate breast and thyroid cancer diagnosis.

Koios DS is built on an ensemble of algorithms trained by a proprietary dataset of over 2 million ultrasound images. By analyzing 17.9k features per image, the software uses artificial intelligence to accurately and successfully classify and render cancer risk assessment.
FDA-Cleared CE Marked Billable Procedure

The Power of Smart Ultrasound

Koios Smart Ultrasound® software reduces avoidable biopsy procedures and unnecessary follow-up appointments as well as decreases patient stress, unecessary out-of-pocket expenses from false positives, over-treatment and human error. And more!
Benign tissue biopsy results reduced by 35-40%
Follow-up appointments reduced by 40%
For every 10,000 cancer cases analyzed…
more cancers are found early
fewer biopsies are ordered
in treatment spend is saved
These figures ultimately result in allowing for 25 additional patients per day, 49% less interpretation time and a 50-109x ROI to the payer.
Learn more about our software solutions.
Dr. Bobbi Ring
Dr. Bobbi Ring
Co-Section Chief at Main Street Radiology / NY Presbyterian

“... a great example... a second lesion had really benign features, but I was surprised when I ran Koios it was a BI- RADS 4. We biopsied the lesion and it was cancer.”

“... tiny ones that we cannot always assess easily, that's where AI technology really helps.”

1,000+ Cases Analyzed
Dr. Amy Patel
Dr. Amy Patel
Associate Professor Director of Women's Imagingat Liberty Hospital

“[Koios] just provides that precision diagnostic accuracy... to ensure we're doing the best for patients.”

“... It's very amazing because these seconds, as we all know, add up to minutes, minutes to hours. We see value in that.”

500+ Cases Analyzed
Dr. Lai Ming Yu
Dr. Lai Ming Yu
Breast Radiologist at Main Street Radiology / NY Presbyterian

“... you're recommending less biopsies for things that are really benign and not recommending short-term follow-ups… Those are significant changes in a practice.

“... when I can save a six-month follow-up, it's very useful...”

1,400+ Cases Analyzed

Active Worldwide

28 Countries 101 Installations 1-2 New Sites Per Week
Africa (2)
  • Kenya
  • South Africa
Asia (3)
  • Singapore (2)
  • Taiwan
Central/South America (25)
  • Argentina (11)
  • Brazil (4)
  • Chile
  • Ecuador (2)
  • Guyana
  • Mexico (2)
  • Paraguay
  • Peru (3)
  • Venezuela
Europe/EU (22)
  • Germany
  • Italy
  • Moldova
  • Spain (10)
  • Turkey (4)
  • UK (2)
Gulf Region (6)
  • Kuwait
  • QatarSaudi (3)
  • UAE
United States (37)
  • California (2)
  • Colorado
  • Connecticut
  • Florida
  • Hawaii
  • Illinois (2)
  • Kansas
  • Massachusetts (2)
  • Michigan (2)
  • Missouri (2)
  • New Jersey
  • New York (7)
  • North Carolina
  • Ohio
  • Pennsylvania (3)
  • Rhode Island
  • Texas (2)
  • Vermont (2)
  • Virginia
  • Washington
  • Washington DC (2)
*Activation data as of July 31, 2022

Get Started

Ready for a Koios DS installation? Interested in learning more?
Get in Touch